Theravance (THRX +2.4%) and GlaxoSmithKline (GSK +0.6%) have submitted a New Drug Application...
Theravance (THRX +2.4%) and GlaxoSmithKline (GSK +0.6%) have submitted a New Drug Application for the investigational drug UMEC/VI (LAMA/LABA), named Anoro Ellipta, which is a potential treatment for patients with chronic obstructive pulmonary disease. The companies also intend to file regulatory applications in the European Union as well as other countries in the coming year.
From other sites
at Nasdaq.com (Mar 25, 2015)
Theravance : GSK and Theravance Update on Outcome of US FDA Advisory Committee on BREO ELLIPTA in Asthmaat 4-traders.com (Mar 25, 2015)
at Zacks.com (Mar 24, 2015)
at Zacks.com (Mar 20, 2015)
at Zacks.com (Mar 11, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs